The "Nacimbio" pharmaceutical holding, part of Rostec, has become the owner of a Eurasian patent for its own technology for producing immunoglobulin class G, which is used in the treatment of COVID-19. The drug "COVID-globulin" was created on the basis of this technology.
"COVID-globulin" is a unique development of our scientists, which was put into circulation at the height of the pandemic. The novelty has replenished the line of new drugs derived from blood plasma, in the production of which the company's technological know-how is used. It allows to obtain virus-safe and effective products by including several additional stages of purification. The Eurasian patent will allow us to protect immunoglobulin from unfair competition.
"COVID-globulin", which is a highly purified preparation of human immunoglobulin against COVID-19, isolated from the blood plasma of donors containing antibodies to the SARS-CoV-2 virus.
According to the results of a double-blind placebo-controlled comparative study, 7 out of 10 patients receiving "COVID-Globulin" as part of complex therapy reduced the risk of the disease progressing to a more severe form. In particular, therapy in 70% of cases prevented the development of such complications arising from coronavirus infection as the appearance of a cytokine storm, renal failure, thromboembolic complications, the development of acute respiratory distress syndrome, an increase in the degree of lung damage and a deterioration in clinical symptoms. At the same time, the greatest effectiveness of "COVID-globulin" was demonstrated when used at an early stage of the disease.
